docetaxel

P2, N=702, Recruiting, West German Study Group | Active, not recruiting --> Recruiting | N=402 --> 702 | Trial completion date: Jun 2029 --> Sep 2030 | Trial primary completion date: Jun 2025 --> Jun 2030

Six prognostic genes, particularly RAB25 and PLAU, influence ESCC progression and immune microenvironment remodeling.

P3, N=700, Not yet recruiting, Qilu Pharmaceutical Co., Ltd.

She received six cycles of neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab. Persistent radiologic abnormalities may represent residual mucin rather than viable tumor cells, underscoring a potential limitation of imaging-based response evaluation. This report provides insight into response interpretation in this rare entity and supports the need for cautious clinical decision-making.

We retrospectively analyzed 148 patients with mHSPC treated with either ARPI (abiraterone, enzalutamide, or apalutamide) plus androgen deprivation therapy (ADT) (n = 98) or docetaxel plus ADT (n = 50). In this real-world cohort, ARPI-based therapy was associated with an improvement in rPFS compared with docetaxel, while OS outcomes remained comparable. In the absence of direct randomized comparisons, these findings may provide supportive real-world evidence for the clinical relevance of ARPI-based therapy as a first-line treatment option for patients with mHSPC.

P3, N=356, Recruiting, Astellas Pharma Global Development, Inc. | Not yet recruiting --> Recruiting

Knockdown of IGFL2 resensitizes resistant cells to DTX both in vitro and in mouse xenograft models. These findings establish IGFL2 as a regulator of DTX resistance via TLR4 signaling, suggesting its relevance as a therapeutic target for overcoming chemoresistance in GC.

This nine-BRM prognostic model serves as a potential prognostic stratification tool that may complement existing clinical parameters in evaluating the outcomes of KIRC patients.

P2, N=34, Not yet recruiting, Abramson Cancer Center at Penn Medicine | Initiation date: Apr 2026 --> Sep 2026

As postoperative adjuvant therapy, she received four cycles of doxorubicin and cyclophosphamide during pregnancy, followed by four cycles of docetaxel after delivery, along with tamoxifen and tegafur-gimeracil-oteracil potassium. She underwent staged risk-reducing salpingo-oophorectomy and CRRM after surgery for left breast cancer. Even in pregnancy-associated breast cancer complicated by HBOC, management should be individualized with careful consideration of safety, and the timing of each intervention should be determined according to the specific clinical circumstances of each patient.

Herein, we report a chemoimmunotherapeutic fibrin sealant (CI-sealant) as a new postsurgical adjuvant therapy that converts the surgical cavity into an in situ "drug-immune depot" with localized release of immunogenic docetaxel/volasertib dual-drug nanocombo (iNCombo) and galunisertib, a TGF-β inhibitor that relieves immune suppression. Post-surgery adjuvant therapy with CI-sealant significantly prevents tumor recurrence in both murine 4 T1-Luc breast tumor and B16F10 melanoma models. This chemoimmunotherapeutic sealant opens a promising strategy for postsurgical adjuvant therapy of malignant tumors.

In contrast, tumors that do not respond to chemotherapy harbor different genetic changes that help them survive and grow. These findings may help physicians choose more effective and personalized treatments in the future.